Argireline vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Argireline
Argireline (Acetyl Hexapeptide-3) is a widely-used cosmetic peptide that reduces wrinkle depth by inhibiting neurotransmitter release. One of the first 'Botox-like' peptides developed for topical use.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Argireline | Exenatide |
|---|---|---|
| Mechanism | Inhibits the formation of the SNARE complex required for neurotransmitter release, reducing the intensity of muscle contractions that cause expression lines. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Topical: 5-10% concentration in serums, applied twice daily. Higher concentrations used in professional treatments. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Topical application to clean skin. Most effective on expression lines (forehead, crow's feet). Consistent use required for visible results. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Generally very well-tolerated. Occasional mild irritation or dryness. No systemic absorption at cosmetic doses. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |